Parkinson Disease Drug Industry Research Report 2024

February 2024 | 104 pages | ID: P2368B63D7ACEN
APO Research

Abstracts

This report aims to provide a comprehensive presentation of the global market for Parkinson Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson Disease Drug.

The Parkinson Disease Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Parkinson Disease Drug market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Parkinson Disease Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

• Merck
• Akorn
• GSK
• Novartis
• Boehringer Ingelheim
• Teva Pharmaceutical
• Abbvie
• Kyowa Hakko Kirin Pharma
• Astellas Pharma
• Desitin Arzneimittel
• Endo Pharmaceuticals
• F.Hoffmann-La Roche
• H.Lundbeck
• Valeant
• Apokyn
• Orion
• Stada Arzneimittel
• US WorldMeds
• Bausch Health

Product Type Insights

Global markets are presented by Parkinson Disease Drug type, along with growth forecasts through 2030. Estimates on revenue are based on the price in the supply chain at which the Parkinson Disease Drug are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).

Parkinson Disease Drug segment by Type

• Sinemet-CR
• Trastal
• Madopar
• COMT Inhibitor
• Other

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).

This report also outlines the market trends of each segment and consumer behaviors impacting the Parkinson Disease Drug market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Parkinson Disease Drug market.

Parkinson Disease Drug Segment by Application

• Under 40 Years Old
• 40-65 Years Old
• Above 65 Years Old

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2019-2030.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.

• North America
• United States
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Nordic Countries
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Parkinson Disease Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Parkinson Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Parkinson Disease Drug industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson Disease Drug.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Parkinson Disease Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Contents

1 PREFACE

1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
  1.5.1 Secondary Sources
  1.5.2 Primary Sources

2 MARKET OVERVIEW

2.1 Product Definition
2.2 Parkinson Disease Drug by Type
  2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
  1.2.2 Sinemet-CR
  1.2.3 Trastal
  1.2.4 Madopar
  1.2.5 COMT Inhibitor
  1.2.6 Other
2.3 Parkinson Disease Drug by Application
  2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
  2.3.2 Under 40 Years Old
  2.3.3 40-65 Years Old
  2.3.4 Above 65 Years Old
2.4 Assumptions and Limitations

3 PARKINSON DISEASE DRUG BREAKDOWN DATA BY TYPE

3.1 Global Parkinson Disease Drug Historic Market Size by Type (2019-2024)
3.2 Global Parkinson Disease Drug Forecasted Market Size by Type (2025-2030)

4 PARKINSON DISEASE DRUG BREAKDOWN DATA BY APPLICATION

4.1 Global Parkinson Disease Drug Historic Market Size by Application (2019-2024)
4.2 Global Parkinson Disease Drug Forecasted Market Size by Application (2019-2024)

5 GLOBAL GROWTH TRENDS

5.1 Global Parkinson Disease Drug Market Perspective (2019-2030)
5.2 Global Parkinson Disease Drug Growth Trends by Region
  5.2.1 Global Parkinson Disease Drug Market Size by Region: 2019 VS 2023 VS 2030
  5.2.2 Parkinson Disease Drug Historic Market Size by Region (2019-2024)
  5.2.3 Parkinson Disease Drug Forecasted Market Size by Region (2025-2030)
5.3 Parkinson Disease Drug Market Dynamics
  5.3.1 Parkinson Disease Drug Industry Trends
  5.3.2 Parkinson Disease Drug Market Drivers
  5.3.3 Parkinson Disease Drug Market Challenges
  5.3.4 Parkinson Disease Drug Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

6.1 Global Top Parkinson Disease Drug Players by Revenue
  6.1.1 Global Top Parkinson Disease Drug Players by Revenue (2019-2024)
  6.1.2 Global Parkinson Disease Drug Revenue Market Share by Players (2019-2024)
6.2 Global Parkinson Disease Drug Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Parkinson Disease Drug Head office and Area Served
6.4 Global Parkinson Disease Drug Players, Product Type & Application
6.5 Global Parkinson Disease Drug Players, Date of Enter into This Industry
6.6 Global Parkinson Disease Drug Market CR5 and HHI
6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

7.1 North America Parkinson Disease Drug Market Size (2019-2030)
7.2 North America Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Parkinson Disease Drug Market Size by Country (2019-2024)
7.4 North America Parkinson Disease Drug Market Size by Country (2025-2030)
7.5 United States
7.6 Canada

8 EUROPE

8.1 Europe Parkinson Disease Drug Market Size (2019-2030)
8.2 Europe Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Parkinson Disease Drug Market Size by Country (2019-2024)
8.4 Europe Parkinson Disease Drug Market Size by Country (2025-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries

9 ASIA-PACIFIC

9.1 Asia-Pacific Parkinson Disease Drug Market Size (2019-2030)
9.2 Asia-Pacific Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Parkinson Disease Drug Market Size by Country (2019-2024)
9.4 Asia-Pacific Parkinson Disease Drug Market Size by Country (2025-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia

10 LATIN AMERICA

10.1 Latin America Parkinson Disease Drug Market Size (2019-2030)
10.2 Latin America Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Parkinson Disease Drug Market Size by Country (2019-2024)
10.4 Latin America Parkinson Disease Drug Market Size by Country (2025-2030)
9.4 Mexico
9.5 Brazil

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Parkinson Disease Drug Market Size (2019-2030)
11.2 Middle East & Africa Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Parkinson Disease Drug Market Size by Country (2019-2024)
11.4 Middle East & Africa Parkinson Disease Drug Market Size by Country (2025-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE

12 PLAYERS PROFILED

11.1 Merck
  11.1.1 Merck Company Detail
  11.1.2 Merck Business Overview
  11.1.3 Merck Parkinson Disease Drug Introduction
  11.1.4 Merck Revenue in Parkinson Disease Drug Business (2017-2022)
  11.1.5 Merck Recent Development
11.2 Akorn
  11.2.1 Akorn Company Detail
  11.2.2 Akorn Business Overview
  11.2.3 Akorn Parkinson Disease Drug Introduction
  11.2.4 Akorn Revenue in Parkinson Disease Drug Business (2017-2022)
  11.2.5 Akorn Recent Development
11.3 GSK
  11.3.1 GSK Company Detail
  11.3.2 GSK Business Overview
  11.3.3 GSK Parkinson Disease Drug Introduction
  11.3.4 GSK Revenue in Parkinson Disease Drug Business (2017-2022)
  11.3.5 GSK Recent Development
11.4 Novartis
  11.4.1 Novartis Company Detail
  11.4.2 Novartis Business Overview
  11.4.3 Novartis Parkinson Disease Drug Introduction
  11.4.4 Novartis Revenue in Parkinson Disease Drug Business (2017-2022)
  11.4.5 Novartis Recent Development
11.5 Boehringer Ingelheim
  11.5.1 Boehringer Ingelheim Company Detail
  11.5.2 Boehringer Ingelheim Business Overview
  11.5.3 Boehringer Ingelheim Parkinson Disease Drug Introduction
  11.5.4 Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2017-2022)
  11.5.5 Boehringer Ingelheim Recent Development
11.6 Teva Pharmaceutical
  11.6.1 Teva Pharmaceutical Company Detail
  11.6.2 Teva Pharmaceutical Business Overview
  11.6.3 Teva Pharmaceutical Parkinson Disease Drug Introduction
  11.6.4 Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2017-2022)
  11.6.5 Teva Pharmaceutical Recent Development
11.7 Abbvie
  11.7.1 Abbvie Company Detail
  11.7.2 Abbvie Business Overview
  11.7.3 Abbvie Parkinson Disease Drug Introduction
  11.7.4 Abbvie Revenue in Parkinson Disease Drug Business (2017-2022)
  11.7.5 Abbvie Recent Development
11.8 Kyowa Hakko Kirin Pharma
  11.8.1 Kyowa Hakko Kirin Pharma Company Detail
  11.8.2 Kyowa Hakko Kirin Pharma Business Overview
  11.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Introduction
  11.8.4 Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2017-2022)
  11.8.5 Kyowa Hakko Kirin Pharma Recent Development
11.9 Astellas Pharma
  11.9.1 Astellas Pharma Company Detail
  11.9.2 Astellas Pharma Business Overview
  11.9.3 Astellas Pharma Parkinson Disease Drug Introduction
  11.9.4 Astellas Pharma Revenue in Parkinson Disease Drug Business (2017-2022)
  11.9.5 Astellas Pharma Recent Development
11.10 Desitin Arzneimittel
  11.10.1 Desitin Arzneimittel Company Detail
  11.10.2 Desitin Arzneimittel Business Overview
  11.10.3 Desitin Arzneimittel Parkinson Disease Drug Introduction
  11.10.4 Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2017-2022)
  11.10.5 Desitin Arzneimittel Recent Development
11.11 Endo Pharmaceuticals
  11.11.1 Endo Pharmaceuticals Company Detail
  11.11.2 Endo Pharmaceuticals Business Overview
  11.11.3 Endo Pharmaceuticals Parkinson Disease Drug Introduction
  11.11.4 Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2017-2022)
  11.11.5 Endo Pharmaceuticals Recent Development
11.12 F.Hoffmann-La Roche
  11.12.1 F.Hoffmann-La Roche Company Detail
  11.12.2 F.Hoffmann-La Roche Business Overview
  11.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Introduction
  11.12.4 F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2017-2022)
  11.12.5 F.Hoffmann-La Roche Recent Development
11.13 H.Lundbeck
  11.13.1 H.Lundbeck Company Detail
  11.13.2 H.Lundbeck Business Overview
  11.13.3 H.Lundbeck Parkinson Disease Drug Introduction
  11.13.4 H.Lundbeck Revenue in Parkinson Disease Drug Business (2017-2022)
  11.13.5 H.Lundbeck Recent Development
11.14 Valeant
  11.14.1 Valeant Company Detail
  11.14.2 Valeant Business Overview
  11.14.3 Valeant Parkinson Disease Drug Introduction
  11.14.4 Valeant Revenue in Parkinson Disease Drug Business (2017-2022)
  11.14.5 Valeant Recent Development
11.15 Apokyn
  11.15.1 Apokyn Company Detail
  11.15.2 Apokyn Business Overview
  11.15.3 Apokyn Parkinson Disease Drug Introduction
  11.15.4 Apokyn Revenue in Parkinson Disease Drug Business (2017-2022)
  11.15.5 Apokyn Recent Development
11.16 Orion
  11.16.1 Orion Company Detail
  11.16.2 Orion Business Overview
  11.16.3 Orion Parkinson Disease Drug Introduction
  11.16.4 Orion Revenue in Parkinson Disease Drug Business (2017-2022)
  11.16.5 Orion Recent Development
11.17 Stada Arzneimittel
  11.17.1 Stada Arzneimittel Company Detail
  11.17.2 Stada Arzneimittel Business Overview
  11.17.3 Stada Arzneimittel Parkinson Disease Drug Introduction
  11.17.4 Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2017-2022)
  11.17.5 Stada Arzneimittel Recent Development
11.18 US WorldMeds
  11.18.1 US WorldMeds Company Detail
  11.18.2 US WorldMeds Business Overview
  11.18.3 US WorldMeds Parkinson Disease Drug Introduction
  11.18.4 US WorldMeds Revenue in Parkinson Disease Drug Business (2017-2022)
  11.18.5 US WorldMeds Recent Development
11.19 Bausch Health
  11.19.1 Bausch Health Company Detail
  11.19.2 Bausch Health Business Overview
  11.19.3 Bausch Health Parkinson Disease Drug Introduction
  11.19.4 Bausch Health Revenue in Parkinson Disease Drug Business (2017-2022)
  11.19.5 Bausch Health Recent Development

13 REPORT CONCLUSION

14 DISCLAIMER